Invivyd, Inc. - Common Stock IVVD 深 沪
已收盘 09-20 16:00:00 美东时间
1.20
-0.020
-1.64%
华盛通- 最 高1.24
- 今 开1.19
- 成交量 124.70万股
- 最 低 1.18
- 昨 收 1.22
- 总市值 1.43亿
- 52周最高 5.195
- 市盈率 静 --
- 换手率 1.05%
- 52周最低 0.8116
- 委 比 83.13%
- 总股本 1.19亿
- 历史最高 78.82
- 量 比 3.14
- 振 幅 4.92%
- 历史最低 0.8116
- 每 手 1
- 风险率 1.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Invivyd Reports Ongoing Neutralizing Effect Of PEMGARDA Against Dominant SARS-CoV-2 Variants KP.3.1.1 And LB.1
New pseudovirus in vitro neutralization data show continued neutralizing activity of PEMGARDA™ (pemivibart) against KP.3.1.1, LB.1, and other SARS-CoV-2 variants tested Center for Disease Control reports
09-03 19:29
Invivyd down 18% despite Pemgarda COVID risk reduction data
Patients treated with Invivyd's (NASDAQ:IVVD) Pemgarda (pemibivart) showed an 84% relative risk reduction in symptomatic COVID-19 compared to placebo in a phase 3 trial. In a group of all-comer immuno...
08-28 00:59
Invivyd Joins Russell 2000 And Russell 3000 Indexes
Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that as part of the annual reconstitution of the Russell stock
07-01 19:11
Invivyd, Inc. (NASDAQ:IVVD) Is Expected To Breakeven In The Near Future
Invivyd, Inc. (NASDAQ:IVVD) is possibly approaching a major achievement in its ...
05-29 22:13
HC Wainwright & Co.：重申Invivyd(IVVD.US)评级，由买入调整至买入评级, 目标价15.00美元。
HC Wainwright & Co.：重申Invivyd(IVVD.US)评级，由买入调整至买入评级, 目标价15.00美元。
05-25 00:50
Invivyd Announces CEO Departure and Interim Leadership Change
Invivyd (IVVD) just unveiled an announcement. Invivyd, Inc. has announced the d...
04-12 19:52
Invivyd appoints Jeremy Gowler as interim CEO
Invivyd (NASDAQ:IVVD) said that the company’s board has appointed Jeremy Gowler as interim CEO, effective immediately. Gowler succeeds CEO Dave Hering. The company said a search for a permanent CEO is...
04-12 19:38
Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and Invivyd (IVVD)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
04-09 00:10
Invivyd provides Pemgarda 2024 net product revenue guidance
Invivyd (NASDAQ:IVVD) announced that PEMGARDA is now available for purchase in the U.S. for pre-exposure prophylaxis of COVID-19 in certain adults and adolescents with moderate-to-severe immune compro...
04-05 04:16
Invivyd, Inc.2023财年实现净利润-1.99亿美元，同比增加17.43%
12月31日，Invivyd, Inc.（IVVD.US）公布财报，公告显示公司2023财年净利润为-1.99亿美元，同比增加17.43%；其中营业收入为0....
03-29 14:14
